Targeted Cancer Therapies with Avacta: From Scientific Story to Patient Impact
By Olesia Karvetskaia, Business Development Manager
June 15, 2026
Last Thursday during Venture Road UK, companies from across the Nordics and the UK pitched in front of a mixed audience of investors and industry partners. Our warm congratulations to the winner of the pitch session, Christina Coughlin, CEO of Avacta, who is working on targeted cancer therapy delivery to improve efficacy while reducing side effects for patients.
In this short interview, Christina shares how Avacta is redefining precision oncology with its tumor-targeted delivery platform, and why this matters for patients, clinicians, and partners. She also talks about the story behind Avacta’s approach, how they communicate complex science in a clear value narrative for investors and pharma, and what she sees as the most important ingredients for successful Nordic–UK collaboration in oncology innovation.
Christina Coughlin, CEO of Avacta